Table 3.
Therapeutic options in natalizumab-associated PML | ||
Antiviral therapy | ▪Cidofovir | |
Topotecan | ||
Mefloquine | ||
Cytosine arabinoside | ||
Immunomodulatories | Interferon-beta | |
Interferon-alpha | ||
Interleukin 2 | ||
5HT-2a receptor blockers | ||
Intravenous immunoglobulins | ||
Haematopoietic growth factors | Granulocyte colony stimulating factors | |
Other interventions | Plasmapheresis | |
Leukapheresis |